Comments
Sun Pharma, through its subsidiary, has completed the acquisition of Japan-based Pola Pharma to strengthen its presence in the dermatology segment across the globe. In November 2018, it had entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan. Pola Pharma has two facilities in Saitama to manufacture topical products and injectables.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.